88. Li X, Peterson YK, Inks ES et al (2018) Class I HDAC inhibitors display different antitumor
mechanism in leukemia and prostatic cancer cells depending on their p53 status. J Med Chem
61:2589–2603
89. Ononye SN, VanHeyst MD, Oblak EZ et al (2013) Tropolones as lead-like natural products:
the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett
4:757–761
90. Kleinschek A, Meyners C, Digiorgio E et al (2016) Potent and selective non-hydroxamate
histone deacetylase 8 inhibitors. ChemMedChem 11:2598–2606
91. Ontoria JM, Altamura S, Di Marco A et al (2009) Identification of novel, selective, and stable
inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic
activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem
52:6782–6789
92. Boskovic ZV, Kemp MM, Freedy AM et al (2016) Inhibition of zinc-dependent histone
deacetylases with a chemically triggered electrophile. ACS Chem Biol 11:1844–1851
93. Millard CJ, Watson PJ, Fairall L et al (2017) Targeting class I histone deacetylases in a
“complex” environment. Trends Pharmacol Sci 38:363–377
94. Villagra A, Sahakian E, Seto E (2016) Preparation and biochemical analysis of classical
histone deacetylases. Methods Enzymol 573:161–181
95. Newbold A, Falkenberg KJ, Prince HM et al (2016) How do tumor cells respond to HDAC
inhibition? FEBS J 283:4032–4046
96. Bolden JE, Shi W, Jankowski K et al (2013) HDAC inhibitors induce tumor-cell-selective
pro-apoptotic transcriptional responses. Cell Death Dis 4:e519
97. Tiffon C, Adams J, van der Fits L et al (2011) The histone deacetylase inhibitors vorinostat and
romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J
Pharmacol 162:1590–1602
98. Das Gupta K, Shakespear MR, Iyer A et al (2016) Histone deacetylases in monocyte/
macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases. Clin Trans Immunol 5:e62
99. Zhang Q, Dai Y, Cai Z et al (2018) HDAC inhibitors: novel immunosuppressants for Allo- and
Xeno- transplantation. Chem Select 3:176–187
100. Thorlund K, Horwitz MS, Fife BT et al (2017) Landscape review of current HIV ‘kick and kill’
cure research – some kicking, not enough killing. BMC Infect Dis 17:595
101. Ghosh SK, Perrine SP, Williams RM et al (2012) Histone deacetylase inhibitors are potent
inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral
agents. Blood 119:1008–1017
102. Warnault V, Darcq E, Levine A et al (2013) Chromatin remodeling – a novel strategy to
control excessive alcohol drinking. Transl Psychiatry 3:e231
103. Qin L, Ma K, Wang ZJ et al (2018) Social deficits in Shank3-deficient mouse models of autism
are rescued by histone deacetylase (HDAC) inhibition. Nat Neurosci 21:564–575
104. Ooi JY, Tuano NK, Rafehi H et al (2015) HDAC inhibition attenuates cardiac hypertrophy by
acetylation and deacetylation of target genes. Epigenetics 10:418–430
105. Akimova T, Beier UH, Liu Y et al (2012) Histone/protein deacetylases and T-cell immune
responses. Blood 119:2443–2451
106. Tsuji G, Okiyama N, Villarroel VA et al (2015) Histone deacetylase 6 inhibition impairs
effector CD8 T-cell functions during skin inflammation. J Allergy Clin Immunol
135:1228–1239
107. Bowers ME, Xia B, Carreiro S et al (2015) The class I HDAC inhibitor RGFP963 enhances
consolidation of cued fear extinction. Learn Mem 22:225–231
108. Bodas M, Mazur S, Min T et al (2018) Inhibition of histone-deacetylase activity rescues
inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune
responses. Respir Res 19:2
26
A. Ganesan
mechanism in leukemia and prostatic cancer cells depending on their p53 status. J Med Chem
61:2589–2603
89. Ononye SN, VanHeyst MD, Oblak EZ et al (2013) Tropolones as lead-like natural products:
the development of potent and selective histone deacetylase inhibitors. ACS Med Chem Lett
4:757–761
90. Kleinschek A, Meyners C, Digiorgio E et al (2016) Potent and selective non-hydroxamate
histone deacetylase 8 inhibitors. ChemMedChem 11:2598–2606
91. Ontoria JM, Altamura S, Di Marco A et al (2009) Identification of novel, selective, and stable
inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic
activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem
52:6782–6789
92. Boskovic ZV, Kemp MM, Freedy AM et al (2016) Inhibition of zinc-dependent histone
deacetylases with a chemically triggered electrophile. ACS Chem Biol 11:1844–1851
93. Millard CJ, Watson PJ, Fairall L et al (2017) Targeting class I histone deacetylases in a
“complex” environment. Trends Pharmacol Sci 38:363–377
94. Villagra A, Sahakian E, Seto E (2016) Preparation and biochemical analysis of classical
histone deacetylases. Methods Enzymol 573:161–181
95. Newbold A, Falkenberg KJ, Prince HM et al (2016) How do tumor cells respond to HDAC
inhibition? FEBS J 283:4032–4046
96. Bolden JE, Shi W, Jankowski K et al (2013) HDAC inhibitors induce tumor-cell-selective
pro-apoptotic transcriptional responses. Cell Death Dis 4:e519
97. Tiffon C, Adams J, van der Fits L et al (2011) The histone deacetylase inhibitors vorinostat and
romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J
Pharmacol 162:1590–1602
98. Das Gupta K, Shakespear MR, Iyer A et al (2016) Histone deacetylases in monocyte/
macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases. Clin Trans Immunol 5:e62
99. Zhang Q, Dai Y, Cai Z et al (2018) HDAC inhibitors: novel immunosuppressants for Allo- and
Xeno- transplantation. Chem Select 3:176–187
100. Thorlund K, Horwitz MS, Fife BT et al (2017) Landscape review of current HIV ‘kick and kill’
cure research – some kicking, not enough killing. BMC Infect Dis 17:595
101. Ghosh SK, Perrine SP, Williams RM et al (2012) Histone deacetylase inhibitors are potent
inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral
agents. Blood 119:1008–1017
102. Warnault V, Darcq E, Levine A et al (2013) Chromatin remodeling – a novel strategy to
control excessive alcohol drinking. Transl Psychiatry 3:e231
103. Qin L, Ma K, Wang ZJ et al (2018) Social deficits in Shank3-deficient mouse models of autism
are rescued by histone deacetylase (HDAC) inhibition. Nat Neurosci 21:564–575
104. Ooi JY, Tuano NK, Rafehi H et al (2015) HDAC inhibition attenuates cardiac hypertrophy by
acetylation and deacetylation of target genes. Epigenetics 10:418–430
105. Akimova T, Beier UH, Liu Y et al (2012) Histone/protein deacetylases and T-cell immune
responses. Blood 119:2443–2451
106. Tsuji G, Okiyama N, Villarroel VA et al (2015) Histone deacetylase 6 inhibition impairs
effector CD8 T-cell functions during skin inflammation. J Allergy Clin Immunol
135:1228–1239
107. Bowers ME, Xia B, Carreiro S et al (2015) The class I HDAC inhibitor RGFP963 enhances
consolidation of cued fear extinction. Learn Mem 22:225–231
108. Bodas M, Mazur S, Min T et al (2018) Inhibition of histone-deacetylase activity rescues
inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune
responses. Respir Res 19:2
26
A. Ganesan